BME100 f2014:Group19 L1

BME 100 Fall 2014	Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help
OUR TEAM LAB 1 WRITE-UP Independent and Dependent Variables The independent variable is the amount of lipopolysaccharide given to the elderly; the independent variable is the amount of the Inflammotin protein found in the elderly subsequent to treatment. Experimental Design Groups Four separate groups will be tested. There will be a control group given a placebo. A second group will be given a 3mg dose of lipopolysaccharide; a third group, 7mg dose, and the fourth, a 10mg dose. Age Because the agent is specifically being tested for the elderly, the ages of the selected subjects will not be younger than 65. Number of subjects per group Each group will contain 25 participants, for a total of 100 participants. Subject Selection Subjects of retiring age and older will be chosen; no individual older than 75 will be chosen, due to increased incidence of conflicting medical issues among those of age >75. There will be no distinction as to race or gender among the subjects chosen; as diverse a population as possible will be chosen in this regard. The only patients that will be deliberately excluded are those currently taking anti-inflammatory drugs or with preexisting inflammatory conditions. Subjects will also be required to fill out what prescription or over the counter medicine they are taking or may take to reduce the chance of any conflictions between drugs. Sources of Error and Bias Discrepancies between relative body weight and composition, concurrent medications, and differing lifestyles will cause variations in the data gathered. Genetic predispositions, environmental factors, and different rates of metabolism between the participants will also affect the data. Most of these discrepancies can be eliminated through greater sample sizes. If greater funding were provided for the experiment, larger sample sizes would be possible. Bias can be minimized by conducting a double-blind experiment. Neither the test subjects nor the distributor of the dosages will be aware of the type of drug they will be receiving. Test subjects will be numbered, dosages will be distributed without identifying information and test results will be reported using only the assigned patient number. Genetic bias can also be eliminated by having medical history research done on families and ancestors.